Bayesian Capital Management LP Buys Shares of 3,306 United Therapeutics Co. (NASDAQ:UTHR)

Bayesian Capital Management LP bought a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,306 shares of the biotechnology company's stock, valued at approximately $1,166,000.

A number of other institutional investors have also recently bought and sold shares of the business. World Investment Advisors LLC acquired a new stake in United Therapeutics during the third quarter worth approximately $393,000. Franklin Resources Inc. increased its position in United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock worth $89,532,000 after acquiring an additional 123,929 shares during the period. GAMMA Investing LLC increased its holdings in shares of United Therapeutics by 29.0% during the fourth quarter. GAMMA Investing LLC now owns 752 shares of the biotechnology company's stock worth $265,000 after purchasing an additional 169 shares during the period. Everence Capital Management Inc. bought a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $487,000. Finally, CWA Asset Management Group LLC bought a new position in United Therapeutics during the 4th quarter worth $1,914,000. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Trading Down 2.1 %

Shares of NASDAQ:UTHR traded down $6.58 during mid-day trading on Friday, hitting $301.42. 335,344 shares of the company traded hands, compared to its average volume of 440,265. The stock has a market cap of $13.60 billion, a P/E ratio of 13.24, a P/E/G ratio of 0.97 and a beta of 0.58. The stock has a 50-day moving average price of $300.53 and a two-hundred day moving average price of $342.14. United Therapeutics Co. has a 12-month low of $263.56 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the prior year, the company posted $6.17 earnings per share. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. As a group, analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the subject of several recent analyst reports. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective for the company in a research report on Monday, April 21st. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Morgan Stanley raised their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. HC Wainwright reiterated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Finally, Wells Fargo & Company reissued an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $392.00.

Insiders Place Their Bets

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the transaction, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $956,195.85. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 75,500 shares of company stock valued at $24,245,880 in the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.